Vical Announces News Release and Conference Call Schedule For First Quarter 2001 Financial Results

Apr 30, 2001, 01:00 ET from Vical Incorporated

    SAN DIEGO, April 30 /PRNewswire/ -- Vical Incorporated (Nasdaq:   VICL)
 today announced that the company will release financial results for first
 quarter 2001 after the close of trading (4:00 p.m. Eastern Time) on Monday,
 May 7, and conduct a conference call with invited analysts and institutional
 investors at noon Eastern Time on Tuesday, May 8.
     The call is open on a listen-only basis to any interested parties.  The
 call also will be available live via webcast at
 www.videonewswire.com/VICAL/050801/.  The archived webcast will be available
 for seven days at www.videonewswire.com/VICAL/050801/.  To listen to the call,
 please dial 706-679-5468 at least ten minutes before the scheduled starting
 time and ask for the Vical conference call.  A replay of the call will be
 available for 48 hours beginning about an hour after the call.  To listen to
 the replay, please dial 706-645-9291 and enter conference identification
 number 898039.
     Invited analysts and institutional investors may ask questions during the
 conference call.  Others may submit questions before the call by e-mail
 addressed to info@vical.com or by fax to 858-646-1150.  Submitted questions
 will be screened for appropriateness and general interest.  Selected questions
 will be answered as time permits at the end of the call.
 
     Vical Incorporated, The Naked DNA Company(TM), is focused on the
 development of pharmaceutical product candidates based on its patented gene
 delivery technology.  A number of therapeutic and vaccine product candidates
 are currently under development for the prevention or treatment of cancer,
 infectious diseases and metabolic disorders by Vical and its collaborative
 partners, including Merck & Co., Pfizer Inc., Aventis Pasteur, Aventis Pharma,
 Human Genome Sciences, Centocor Inc., Merial and Boston Scientific
 Corporation.  Allovectin-7(R), which uses a lipid-DNA complex to help the
 immune system recognize and attack cancer cells, is in Phase II and Phase III
 testing in certain patients with metastatic melanoma and in Phase II testing
 in patients with head and neck cancer.  Leuvectin(TM), which uses a lipid-DNA
 complex to stimulate an immune response against cancer cells, is in Phase II
 testing in patients with prostate cancer.  Vaxid, a naked DNA vaccine to
 prevent relapse of B-cell lymphoma, is in Phase I/II testing.  In
 collaboration with the National Cancer Institute, a naked DNA vaccine to treat
 metastatic melanoma is in Phase I/II testing.  If you are interested in any of
 Vical's clinical trials, please see our website at www.vical.com, or contact
 Tammy Boyce by phone at 858/646-1120 or by e-mail at tboyce@vical.com.
 
     This press release contains forward-looking statements subject to risks
 and uncertainties that could cause actual results to differ materially from
 those projected.  Forward-looking statements include statements about the
 company's focus, collaborative partners, product candidates, and developmental
 status.  Risks and uncertainties include whether any product candidates will
 be shown to be safe and efficacious in clinical trials, the timing of clinical
 trials, whether Vical or its collaborative partners will seek or gain approval
 to market any product candidates, and additional risks set forth in the
 company's filings with the Securities and Exchange Commission.  These
 forward-looking statements represent the company's judgment as of the date of
 this release.  The company disclaims, however, any intent or obligation to
 update these forward-looking statements.
 
     For news releases and other information about the company, visit the Vical
 web site at www.vical.com.
 
                     MAKE YOUR OPINION COUNT -  Click Here
                http://tbutton.prnewswire.com/prn/11690X96387656
 
 

SOURCE Vical Incorporated
    SAN DIEGO, April 30 /PRNewswire/ -- Vical Incorporated (Nasdaq:   VICL)
 today announced that the company will release financial results for first
 quarter 2001 after the close of trading (4:00 p.m. Eastern Time) on Monday,
 May 7, and conduct a conference call with invited analysts and institutional
 investors at noon Eastern Time on Tuesday, May 8.
     The call is open on a listen-only basis to any interested parties.  The
 call also will be available live via webcast at
 www.videonewswire.com/VICAL/050801/.  The archived webcast will be available
 for seven days at www.videonewswire.com/VICAL/050801/.  To listen to the call,
 please dial 706-679-5468 at least ten minutes before the scheduled starting
 time and ask for the Vical conference call.  A replay of the call will be
 available for 48 hours beginning about an hour after the call.  To listen to
 the replay, please dial 706-645-9291 and enter conference identification
 number 898039.
     Invited analysts and institutional investors may ask questions during the
 conference call.  Others may submit questions before the call by e-mail
 addressed to info@vical.com or by fax to 858-646-1150.  Submitted questions
 will be screened for appropriateness and general interest.  Selected questions
 will be answered as time permits at the end of the call.
 
     Vical Incorporated, The Naked DNA Company(TM), is focused on the
 development of pharmaceutical product candidates based on its patented gene
 delivery technology.  A number of therapeutic and vaccine product candidates
 are currently under development for the prevention or treatment of cancer,
 infectious diseases and metabolic disorders by Vical and its collaborative
 partners, including Merck & Co., Pfizer Inc., Aventis Pasteur, Aventis Pharma,
 Human Genome Sciences, Centocor Inc., Merial and Boston Scientific
 Corporation.  Allovectin-7(R), which uses a lipid-DNA complex to help the
 immune system recognize and attack cancer cells, is in Phase II and Phase III
 testing in certain patients with metastatic melanoma and in Phase II testing
 in patients with head and neck cancer.  Leuvectin(TM), which uses a lipid-DNA
 complex to stimulate an immune response against cancer cells, is in Phase II
 testing in patients with prostate cancer.  Vaxid, a naked DNA vaccine to
 prevent relapse of B-cell lymphoma, is in Phase I/II testing.  In
 collaboration with the National Cancer Institute, a naked DNA vaccine to treat
 metastatic melanoma is in Phase I/II testing.  If you are interested in any of
 Vical's clinical trials, please see our website at www.vical.com, or contact
 Tammy Boyce by phone at 858/646-1120 or by e-mail at tboyce@vical.com.
 
     This press release contains forward-looking statements subject to risks
 and uncertainties that could cause actual results to differ materially from
 those projected.  Forward-looking statements include statements about the
 company's focus, collaborative partners, product candidates, and developmental
 status.  Risks and uncertainties include whether any product candidates will
 be shown to be safe and efficacious in clinical trials, the timing of clinical
 trials, whether Vical or its collaborative partners will seek or gain approval
 to market any product candidates, and additional risks set forth in the
 company's filings with the Securities and Exchange Commission.  These
 forward-looking statements represent the company's judgment as of the date of
 this release.  The company disclaims, however, any intent or obligation to
 update these forward-looking statements.
 
     For news releases and other information about the company, visit the Vical
 web site at www.vical.com.
 
                     MAKE YOUR OPINION COUNT -  Click Here
                http://tbutton.prnewswire.com/prn/11690X96387656
 
 SOURCE  Vical Incorporated